Doximity vs Teladoc: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Doximity Inc (DOCS)

Q3 202629 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

July 202629 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

Latest29 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

Teladoc Inc (TDOC)

Q3 20268 Jul – 30 Jul 2026

▼3

Teladoc Cuts Guidance as BetterHelp Collapses; Iran Tensions Add Pressure

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.

July 20268 Jul – 30 Jul 2026

▼3

Teladoc Cuts Guidance as BetterHelp Collapses; Iran Tensions Add Pressure

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.

Latest8 Jul – 30 Jul 2026

▼3

Teladoc Cuts Guidance as BetterHelp Collapses; Iran Tensions Add Pressure

Teladoc slashes full-year revenue guidance on Q2 miss Teladoc reported Q2 revenue of $606.9 million, missing estimates, and lowered full-year revenue guidance to $2.362–$2.447 billion. The stock plunged as much as 29% because the cut signals weaker future sales and profits than investors expected.
This is the single biggest new event directly hitting TDOC's price and future outlook.
BetterHelp segment collapses, dragging down overall results BetterHelp revenue fell 12% to $212.6 million and its adjusted EBITDA plunged 96% to just $0.47 million. This sharp deterioration in a key business line raises serious doubts about Teladoc's growth story and profitability.
It explains the specific business weakness behind the guidance cut and why investors are so negative.
Iran conflict drives bond yields up, pressuring growth stocks Trump's vow to strike Iran pushed oil and bond yields higher, causing a risk-off rotation. Teladoc fell 4% as rising yields make future earnings less valuable today, hitting high-multiple growth stocks like TDOC especially hard.
This macro event adds external pressure on TDOC's valuation, compounding its company-specific troubles.